These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 15951306)

  • 1. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
    Mattei D; Mordini N; Vigna Taglianti R; Bruno B; Rapezzi D; Gallamini A
    Haematologica; 2005 Jun; 90(6):861-2. PubMed ID: 15951306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
    Patriarca F; Prosdocimo S; Tomadini V; Vasciaveo A; Bruno B; Fanin R
    Haematologica; 2005 Feb; 90(2):278-9. PubMed ID: 15710593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
    Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y
    Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
    El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
    Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
    Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
    Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
    Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].
    Vokurka S
    Klin Onkol; 2010; 23(4):242-4. PubMed ID: 20806822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
    Musto P; Falcone A; Sanpaolo G; Guglielmelli T; Zambello R; Balleari E; Catalano L; Spriano M; Cavallo F; La Sala A; Mantuano S; Nobile M; Melillo L; Scalzulli PR; Dell'Olio M; Bodenizza C; Greco MM; Carella AM; Merla E; Carella AM; Boccadoro M; Cascavilla N; Palumbo A
    Leuk Res; 2006 Mar; 30(3):283-5. PubMed ID: 16111749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
    Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA
    Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Kaposztas Z; Kahan BD; Katz SM; Van Buren CT; Cherem L
    Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in the treatment of patients with multiple myeloma.
    Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
    Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.
    Kortüm M; Knop S; Einsele H
    Future Oncol; 2011 Jan; 7(1):135-43. PubMed ID: 21174544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multiple myeloma: an emphasis on new developments.
    Kyle RA; Vincent Rajkumar S
    Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin lesions induced by bortezomib.
    Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J
    Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial therapy in multiple myeloma: investigating the new treatment paradigm.
    Kettle JK; Finkbiner KL; Klenke SE; Baker RD; Henry DW; Williams CB
    J Oncol Pharm Pract; 2009 Sep; 15(3):131-41. PubMed ID: 19276138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.